Drugs Generic: Zoetis (NYSE:ZTS), Mylan (NASDAQ:MYL), Actavis plc (NYSE:ACT), Horizon Pharma (NASDAQ:HZNP), Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Analysts at BMO Capital Markets hoisted their target price on shares of Zoetis (NYSE:ZTS) from $35.00 to $37.00 in a research report issued to clients and investors on Thursday. Zoetis Inc. (NYSE:ZTS) net profit margin is 11.40% and weekly performance is 1.75%. On last trading day company shares ended up $32.55. Analysts mean target price for the company is $35.64. Zoetis Inc. (NYSE:ZTS) distance from 50-day simple moving average (SMA50) is 6.67%.

Mylan Inc. (NASDAQ:MYL) on 11 June announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott’s Actonel® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Mylan Inc. (NASDAQ:MYL) shares fell -0.41% in last trading session and ended the day on $50.41. MYL gross Margin is 44.80% and its return on assets is 4.50%.Mylan Inc. (NASDAQ:MYL) quarterly performance is -4.18%.

Actavis PLC (NYSE:ACT) said Thursday that a U.S. federal court has ruled that its generic version of Novartis’ Exelon Patch infringes certain patents. Actavis plc (NYSE:ACT) shares moved down -0.81% in last trading session and was closed at $215.25, while trading in range of $213.41 – $217.71. Actavis plc (NYSE:ACT) year to date (YTD) performance is 28.13%.

Horizon Pharma Inc. (NASDAQ:HZNP) has secured $300 million in financing to aid in its acquisition of Vidara Therapeutics International. The financing agreement with a group of lenders will replace the $250 million bridge loan commitment received from Deerfield Management Company, L.P., according to Horizon. The company intends to use proceeds to complete the acquisition of Vidara, pay related transaction fees and expenses and for general corporate purposes. Horizon Pharma Inc. (NASDAQ:HZNP) ended the last trading day at $16.32. Company weekly volatility is calculated as 4.63% and price to cash ratio as 11.64.Horizon Pharma Inc. (NASDAQ:HZNP) showed a positive weekly performance of 10.94%.

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced that the Company is set to join the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) weekly performance is 2.93%. On last trading day company shares ended up $2.46. Analysts mean target price for the company is $4.50. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) distance from 50-day simple moving average (SMA50) is 19.14%.